Press Releases

    • March 21, 2023

    Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

    LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    March 16, 2023

    Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

    LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    February 24, 2023

    Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

    Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    February 16, 2023

    Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

    Loughborough, England – February 16, 2023 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...

    Read more
    January 31, 2023

    Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

    LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    January 27, 2023

    Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

    LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    January 26, 2023

    Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

    Nemaura to integrate its proBEATTM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. market. LOUGHBOROUGH, Jan....

    Read more
    January 24, 2023

    Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

    Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients....

    Read more
    November 29, 2022

    Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom

    LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company...

    Read more
    November 15, 2022

    Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

    Loughborough, England, Nov. 15, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more